2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIOGUANYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIOADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-CYTIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENEGUANOSINE – Applicazione in terapia e ricerche cliniche attuali

2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIOGUANYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIOADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-CYTIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENEGUANOSINE

FAQ

Studi clinici in corso su 2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIOGUANYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIOADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-GUANYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-ADENYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-CYTIDYLYL-(3′->5′)-2′-DEOXY-P-THIO-THYMIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-CYTIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENE-5-METHYL-P-THIO-URIDYLYL-(3′->5′)-2′-O, 4′-C-METHYLENEGUANOSINE

Data di inizio: 2024-09-03

Studio sull’Efficacia e Sicurezza a Lungo Termine di GTX-102 nei Pazienti con Sindrome di Angelman

Reclutamento in corso
3 1 1
La ricerca si concentra sulla Sindrome di Angelman, una condizione genetica che causa ritardi nello sviluppo, problemi di equilibrio e coordinazione, e difficoltà di comunicazione. Lo studio esamina l’uso di un farmaco chiamato GTX-102, una soluzione per iniezione, per valutare la sua sicurezza a lungo termine nei pazienti affetti da questa sindrome. Il farmaco è…
Malattie indagate:
- Sindrome di Angelman
Farmaci indagati: